Jardiance Approval History
- FDA approved: Yes (First approved August 1st, 2014)
- Brand name: Jardiance
- Generic name: empagliflozin
- Dosage form: Tablets
- Company: Boehringer Ingelheim Pharmaceuticals, Inc.
- Treatment for: Diabetes, Type 2
Jardiance (empagliflozin) is a sodium glucose co-transporter-2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, and to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.
Development History and FDA Approval Process for Jardiance
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.